Eton Pharmaceuticals ETON Slips 44 as Stock Tests Key Support Levels Investor Skepticism Shadows China Vankes StateBacked Turnaround Efforts CNVS Q1 2026 Earnings EPS Beats Estimates as Company Continues Operational Focus Ambassador Greer Calls for Updated Trade Theory to Reflect Tariffs Industrial Policy and Globalization Costs